Glucotrack Inc. (NASDAQ: GCTK) is pioneering a new approach to diabetes management with its fully implantable continuous blood glucose monitoring (CBGM) system. By forming a Patient Advisory Board (PAB) composed of individuals living with type 1 diabetes, the company has directly incorporated patient feedback into the development of its technology. This innovative system aims to overcome the limitations of current glucose monitoring tools, such as inaccuracies, false alarms, and the emotional toll on patients.
The CBGM system by Glucotrack offers long-term functionality with minimal maintenance, eliminates the need for adhesives, and provides direct blood glucose measurements for improved accuracy. A first-in-human feasibility study in Brazil showed promising results, with no serious adverse events and a high data capture rate. The system's accuracy was notably better than many commercially available CGM systems, achieving a Median Absolute Relative Difference (MARD) of 6.7%.
With ethical approval for a year-long clinical study in Australia, Glucotrack is set to further evaluate the performance and safety of its CBGM system. The study, led by renowned diabetes researchers, aims to enroll up to 30 patients on intensive insulin therapy. The company's participation in the 2025 American Diabetes Association Scientific Sessions will showcase the potential of its technology to redefine diabetes care.
Glucotrack's efforts represent a significant step forward in addressing the trust deficit among diabetes patients towards current monitoring solutions. By focusing on the human aspect of diabetes management, the company is not just innovating technology but also improving the quality of life for those affected by the condition.
